Managing unipolar depression in pregnancy

Current Opinion in Psychiatry

Volumn 22, Issue 1, 2009, Pages 13-18

  Raudzus, Julia ^a   Misri, Shaila ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

Depression; Nonpharmacological; Perinatal; Pharmacological; Pregnancy; Treatment

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; FLUOXETINE; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ACUPUNCTURE; ALTERNATIVE MEDICINE; ANENCEPHALUS; BEHAVIOR DISORDER; CLINICAL FEATURE; COGNITIVE THERAPY; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; CRANIOFACIAL SYNOSTOSIS; DIET SUPPLEMENTATION; EDINBURGH POSTNATAL DEPRESSION SCALE; EXERCISE; HUMAN; MAJOR DEPRESSION; MATERNAL CARE; NEONATAL BEHAVIORAL SYNDROME; OMPHALOCELE; PERINATAL CARE; PERSISTENT PULMONARY HYPERTENSION; PHOTOTHERAPY; PREGNANCY; PRENATAL DRUG EXPOSURE; PSYCHOTHERAPY; REVIEW; RISK ASSESSMENT; RISK FACTOR; TERATOGENICITY;

ABNORMALITIES, DRUG-INDUCED; ANTIDEPRESSIVE AGENTS; COMPLEMENTARY THERAPIES; DEPRESSIVE DISORDER; FEMALE; HUMANS; PHOTOTHERAPY; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS; PSYCHOTHERAPY;

EID: 57749178684     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/YCO.0b013e3283169375     Document Type: Review

References (54)

1. Lusskin SI, Pundiak TM, Habib SM. Perinatal depression: hiding in plain sight. Can J Psychiatry 2007; 52:479-488. This article provides a summary of the prevalence, diagnosis and pathogenesis associated with antenatal depression. It also reviews the risks related to this illness for both mother and fetus.
2. Gavin NI, Gaynes BN, Lohr KN, et al. Perinatal depression: a systematic review of prevalence and incidence. Obstet Gynecol 2005; 106 (5 Pt 1):1071-1083.
3. Bennett HA, Einarson A, Taddio A, et al. Prevalence of depression during pregnancy: systematic review [erratum appears in Obstet Gynecol 2004; 103:1344]. Obstet Gynecol 2004; 103:698-709.
4. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006; 295:499-507.
5. Evans J, Heron J, Patel RR, Wiles N. Depressive symptoms during pregnancy and low birth weight at term: longitudinal study. Br J Psychiatry 2007; 191:84-85. This article provides a different perspective from other studies that have shown an association between depressive symptoms during pregnancy and birth weight.
6. Alder J, Fink N, Bitzer J, et al. Depression and anxiety during pregnancy: a risk factor for obstetric, fetal and neonatal outcome? A critical review of the literature. J Matern Fetal Neonatal Med 2007; 20:189-209. This study demonstrated that enhanced levels of depression and anxiety symptoms during pregnancy contribute independent of other biomedical risk factors to adverse obstetric, fetal and neonatal outcomes.
7. Field T, Diego M, Hernandez-Reif M. Prenatal dysthymia versus major depression effects on the neonate. Infant Behav Dev 2008; 31:190-193. The results of this study showed that both newborns of mothers with dysthymia and major depression had a shorter gestational age, lower birth weight, shorter birth length and less optimal obstetric complication scores.
8. Field T, Diego M, Hernandez-Reif M, et al. Chronic prenatal depression and neonatal outcome. Int J Neurosci 2008; 118:95-103. This study showed less optimal outcomes for neonates of depressed women, including lower gestational age and lower birth weight.
9. Bonari L, Pinto N, Ahn E, et al. Perinatal risks of untreated depression during pregnancy. Can J Psychiatry 2004; 49:726-735.
10. Flynn HA, Blow FC, Marcus SM. Rates and predictors of depression treatment among pregnant women in hospital affiliated obstetrics practices. Gen Hosp Psychiatry 2006; 28:289.
11. Steiner M, Dunn E, Born L. Hormones and mood: from menarche to menopause and beyond. J Affect Disord 2003; 74:67-83.
12. Altshuler LL, Cohen LS, Vitonis AF, et al. The Pregnancy Depression Scale (PDS): a screening tool for depression in pregnancy. Arch Womens Ment Health 2008 [Epub ahead of print]. These researchers sought to develop a brief, convenient, clinician-rated scale to specifically assess depression during pregnancy. To date no other clinician-rated screening tools for depression in pregnancy have been validated.
13. Thoppil J, Riutcel TL, Nalesnik SW. Early intervention for perinatal depression. Am J Obstet Gynecol 2005; 192:1446-1448.
14. Felice E, Saliba J, Grech V, Cox J. Validation of the Maltese version of the Edinburgh Postnatal Depression Scale. Arch Womens Ment Health 2006; 9:75-80.
15. Lee AM, Lam SK, Sze Mun Lau SM, et al. Prevalence, course, and risk factors for antenatal anxiety and depression. Obstet Gynecol 2007; 110:1102-1112.
16. O'Hara MW. Social support, life events, and depression during pregnancy and the puerperium. Arch Gen Psychiatry 1986; 43:569-573.
17. Elsenbruch S, Benson S, Rucke M, et al. Social support during pregnancy: effects on maternal depressive symptoms, smoking and pregnancy outcome. Hum Reprod 2007; 22:869-877. This study demonstrated that lack of social support constitutes an important risk factor for maternal well being during pregnancy and has adverse effects on pregnancy outcomes.
18. Stowe ZN. The onset of postpartum depression: implications for clinical screening in obstetrical and primary care. Am J Obstet Gynecol 2005; 192:522.
19. Ryan D, Milis L, Misri N. Depression during pregnancy. Can Fam Physician 2005; 51:1087-1093.
20. Hollon SD, DeRubeis RJ, Evans MD, et al. Cognitive therapy and pharmacotherapy for depression. Singly and in combination. Arch Gen Psychiatry 1992; 49:774-781.
21. Spinelli MG, Endicott J. Controlled clinical trial of interpersonal psychotherapy versus parenting education program for depressed pregnant women. Am J Psychiatry 2003; 160:555-562.
22. Zlotnick C, Johnson SL, Miller IW, et al. Postpartum depression in women receiving public assistance: pilot study of an interpersonal-therapy- oriented group intervention. Am J Psychiatry 2001; 158:638-640.
23. Oren DA, Wisner KL, Spinelli M, et al. An open trial of morning light therapy for treatment of antepartum depression. Am J Psychiatry 2002; 159:666-669.
24. Krzystanek M, Krupka-Matuszczyk I. Bright light therapy in pregnant women depression - 3 case studies. Psychiatr Pol 2006; 40:261-267.
25. Tuunainen A, Kripke DF, Endo T. Light therapy for nonseasonal depression. Cochrane Database Syst Rev 2008; CD004050.
26. Da Costa D, Rippen N, Dritsa M, Ring A. Self-reported leisure-time physical activity during pregnancy and relationship to psychological well being. J Psychosom Obstet Gynaecol 2003; 24:111-119.
27. Manber R, Schnyer RN, Allen JJ, et al. Acupuncture: a promising treatment for depression during pregnancy. J Affect Disord 2004; 83:89-95.
28. Linde K, Ramirez G, Mulrow CD, et al. St John's wort for depression - an overview and meta-analysis of randomized clinical trials. BMJ 1996; 313:253-258.
29. Su KP, Huang SY, Chiu TH, et al. Omega-3 fatty acids for major depressive disorder during pregnancy: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008; 69:644-651. ω-3 Fatty acids may have therapeutic benefit in depression during pregnancy.
30. Rees AM, Austin MP, Parker GB. Omega-3 fatty acids as a treatment for perinatal depression: randomized double-blind placebo-controlled trial. Aust N Z J Psychiatry 2008; 42:199-205. This study demonstrated that further research is needed to establish whether ω-3 fatty acids are an effective treatment for perinatal depression.
31. Misri S, Kendrick K. Treatment of perinatal mood and anxiety disorders: a review [see comment]. Can J Psychiatry 2007; 52:489-498. This review of treatment of depression in pregnancy explores nonpharmacological and pharmacological treatment modalities and evidence to support them.
32. Yonkers KA. The treatment of women suffering from depression who are either pregnant or breastfeeding. Am J Psychiatry 2007; 164:1457-1459.
33. ACOG Committee on Practice, Bulletins: obstetrics. ACOG Practice Bulletin: clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol 2008; 111:1001-1020. This practice bulletin, designed to aid practitioners in making appropriate decisions in obstetrical and gynecological care, provides an excellent overview of the use of psychiatric medications in this population.
34. Alwan S, Reefhuis J, Rasmussen SA, et al. National Birth Defects Prevention, Study. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007; 356:2684-2692. A large case-control study from multi-site surveillance programs showed that maternal use of SSRIs during early pregnancy was not associated with significantly increased risks of congenital heart defects or of most other categories of birth defects.
35. U.S. Food and Drug Administration. SSRIs and treatment challenges of depression in pregnancy; 2006. http://www.fda.gov/medwatch/safety/2006/safety06. htm#SSRIpreg. [Accessed 22 July 2008].
36. Health Canada. Health Canada advises of potential adverse effects of SSRIs and other antidepressants on newborns; 2004. http://www.hc-sc.gc.ca/ahc- asc/media/advisories-avis/_2004/2004_44-eng.php. [Accessed 22 July 2008].
37. Health Canada. Important safety information on Paxil (paroxetine) and increased risk of cardiac defects following exposure during first trimester of pregnancy: for health professionals. GlaxoSmithKline Inc.; 2005. http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2005/ paxil_4_hpc-cps-eng.php. [Accessed 22 July 2008].
38. Way CM. Safety of newer antidepressants in pregnancy. Pharmacotherapy 2007; 27:546-552. This review provides an overview of recent studies looking at the use of newer antidepressants in pregnancy and discusses them with respect to teratogenicity, fetal effects and neonatal toxicity.
39. Källén B. Antidepressant drugs during pregnancy and infant congenital heart defect. Reprod Toxicol 2006; 21:221.
40. Kallen B. The safety of antidepressant drugs during pregnancy. Expert Opin Drug Saf 2007; 6:357-370. This article discusses known or suspected effects of maternal use of antidepressants during pregnancy on pregnancy outcome.
41. GlaxoSmithKline I. Epidemiology study: updated Preliminary Report on Bupropion and Other Antidepressants, Including Paroxetine, in Pregnancy and the Occurrence of Cardiovascular and Major Congenital Malformation; 2005. http://ctr.gsk.co.uk/Summary/paroxetine/studylist.asp. [Accessed 15 July 2008].
42. Einarson A, Pistelli A, DeSantis M, et al. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry 2008; 165:749-752. This research challenges previous literature that demonstrated an increased risk of cardiovascular birth defects associated with maternal use of paroxetine.
43. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006; 354:579-587.
44. Hernandez-Diaz S, Van Marter U, Werler MM, et al. Risk factors for persistent pulmonary hypertension of the newborn. Pediatrics 2007; 120:e272-e282. Although unable to completely rule out SSRI exposure as a potential risk factor for persistent pulmonary hypertension of the newborn, this study identified that many other maternal, delivery and infant factors were stronger predictors of risk.
45. Koren G, Matsui D, Einarson A, et al. Is maternal use of selective serotonin reuptake inhibitors in the third trimester of pregnancy harmful to neonates? [see comment]. CMAJ 2005; 172:1457-1459.
46. Ferreira E, Carceller AM, Agogue C, et al. Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. Pediatrics 2007; 119:52-59. Neonatal behavioral signs were frequently found in newborns exposed to antidepressant, but symptoms were transient and self-limited.
47. Eyal R, Yaeger D. Poor neonatal adaptation after in utero exposure to duloxetine. Am J Psychiatry 2008; 165:651.
48. Levinson-Castiel R, Merlob P, Linder N, et al. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 2006; 160:173-176.
49. Maschi S, Clavenna A, Campi R, et al. Neonatal outcome following pregnancy exposure to antidepressants: a prospective controlled cohort study. Br J Obstet Gynaecol 2008; 115:283-289. The results of this study do not support an association between antidepressant exposure and unsafe fetal and neonatal outcomes in newborns.
50. Freeman MP. Antenatal depression: navigating the treatment dilemmas. Am J Psychiatry 2007; 164:1162-1165. This article provides a practical approach to the treatment of depression in pregnancy.
51. Hostetter A, Stowe ZN, Strader JR Jr, et al. Dose of selective serotonin uptake inhibitors across pregnancy: clinical implications. Depress Anxiety 2000; 11:51-57.
52. Hendrick V, Stowe ZN, Altshuler LL, et al. Placental passage of antidepressant medications. Am J Psychiatry 2003; 160:993-996.
53. Einarson TR, Einarson A. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf 2005; 14:823-827.
54. Stowe ZN. The pharmacokinetics of sertraline excretion into human breast milk: determinants of infant serum concentrations. J Clin Psychiatry 2003; 64:73.